dabigatran has been researched along with Activated Protein C Resistance in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kadauke, S; Khor, B; Van Cott, EM | 1 |
| Gessoni, F; Gessoni, G; Valle, R; Valverde, S | 1 |
| Debasse, M; Jacquemin, M; Peerlinck, K; Peetermans, M; Schoeters, J; Toelen, J; van Horenbeeck, I; van Ryn, J; Vanassche, T; Vanlinthout, I; Verhamme, P | 1 |
| Caruso, P; Gessoni, F; Gessoni, G; Valle, L; Valle, R; Valverde, S | 1 |
| Baghaei, F; Blixter, IF; Gustafsson, KM; Hillarp, A; Lindahl, TL; Sten-Linder, M; Stigendal, L; Strandberg, K | 1 |
| Adcock, DM; Dwyre, DM; Gosselin, R; Kitchen, S | 1 |
6 other study(ies) available for dabigatran and Activated Protein C Resistance
| Article | Year |
|---|---|
Activated protein C resistance testing for factor V Leiden.
Topics: Activated Protein C Resistance; Adult; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation Tests; Child; Dabigatran; Factor V; Factor Xa; False Positive Reactions; Female; Hirudins; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Fragments; Pipecolic Acids; Pregnancy; Protein C; Recombinant Proteins; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2014 |
The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
Topics: Activated Protein C Resistance; Aged; Aged, 80 and over; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor V; Factor Xa Inhibitors; Female; Heterozygote; Humans; Male; Middle Aged; Partial Thromboplastin Time; Rivaroxaban; Thromboplastin | 2015 |
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
Topics: Activated Protein C Resistance; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibody Specificity; Antithrombins; Blood Coagulation Disorders; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Immunologic; False Negative Reactions; False Positive Reactions; Hemophilia A; Humans; Lupus Coagulation Inhibitor | 2015 |
Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Topics: Activated Protein C Resistance; Antithrombins; Blood Coagulation Tests; Dabigatran; Diagnostic Errors; Factor V; Female; Humans; Male; Mutation; Protein C; Thromboplastin | 2017 |
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Topics: Activated Protein C Resistance; Administration, Oral; Adult; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Female; Fibrinogen; Humans; Male; Middle Aged; Partial Thromboplastin Time; Prothrombin Time; Reproducibility of Results; Thrombin | 2011 |
The effect of dabigatran on select specialty coagulation assays.
Topics: Activated Protein C Resistance; Administration, Oral; Antithrombins; Artifacts; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Diagnostic Errors; Factor VIII; False Positive Reactions; Humans; In Vitro Techniques; Partial Thromboplastin Time; Protein S Deficiency; Prothrombin; Pyridines; Thrombin | 2013 |